MADRID, July 8 (Reuters) - The Grifols family and

Canadian fund Brookfield are in talks to launch a takeover bid

for Spanish drugmaker Grifols that could be worth

around 5.5 billion euros ($5.95 billion), business newspaper

Cinco Dias reported on Sunday, citing unnamed people familiar

with the plans.

According to the report, Grifols' board held an

extraordinary meeting over the weekend to study a preliminary

offer presented by the founding family, which currently controls

about 30% of the company's shares.

The family's aim is to gain access to the company's books in

order to make a final offer in the coming weeks, the report

said, adding that Lazard ( LAZ ) was the sole financial advisor to both

parties.

Neither Grifols nor Brookfield were immediately available

for comment on Monday.

The company's main shareholders - after the descendants of

three brothers who took the company from a small family-owned

laboratory in Barcelona to a global player in the plasma

derivatives business - include the funds Capital, Blackrock ( BLK ),

Europacific and Rokos Global.

Since early January, short-seller fund Gotham City Research

has released several reports accusing Grifols of overstating

earnings and understating debt. The firm's market value has shed

several billion euros since then.

Following Gotham City's reports, Grifols announced

governance changes and revised its reported leverage higher

after market supervisor CNMV required that it change its

calculations.

Last week, Grifols appointed Rahul Srinivasan as chief

financial officer in a management reshuffle and Scranton

Enterprises, an entity tied to the Grifols family, reached an

agreement with a private investor to refinance 377 million euros

of debt in one of its units.

($1 = 0.9240 euros)

(Reporting by David Latona; Editing by)